A multicentre, open label, dose-escalation phase I trial in patients with advanced stage chronic heart failure (CHF)

Trial Profile

A multicentre, open label, dose-escalation phase I trial in patients with advanced stage chronic heart failure (CHF)

Planning
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Carfostin (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Sep 2017 According to a NanoCor Therapeutics media release, the company expects to initiate this trial in 2018.
    • 22 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top